MEDESIS PHARMA (EPA:ALMDP) | Finanzwire

Basculer en Français

8295	Companies
114833	Keywords
55274	Articles
62430	Press releases

Home
Companies
MEDESIS PHARMA

REGULATED PRESS RELEASE

published on 11/20/2024 at 17:45, 17 hours 2 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
REGULATED PRESS RELEASE

published on 10/08/2024 at 08:00, 1 month 13 days ago

MEDESIS PHARMA to participate to the World Congress for Clinical Trials in Alzheimer’s Disease, in Madrid at the end of October 2024 (CTAD, Clinical Trials Alzheimer’s Disease)
BRIEF

published on 09/20/2024 at 08:05, 2 months 1 day ago

Encouraging results from NanoLithium trial on Alzheimer's disease

Biotechnology Alzheimer Nanolithium Clinical Trial Tolérance
REGULATED PRESS RELEASE

published on 07/15/2024 at 08:00, 4 months 6 days ago

MEDESIS PHARMA: 2023 FULL-YEAR BUSINESS AND EARNINGS
REGULATED PRESS RELEASE

published on 03/19/2024 at 18:01, 8 months 1 day ago

Termination of the agreement between NICE and GREEN S.A. and Medesis Pharma
REGULATED PRESS RELEASE

published on 01/29/2024 at 18:00, 9 months 22 days ago

MEDESIS PHARMA : Phase 2 clinical trial for the treatment of Alzheimer's disease - Completion of the 1st phase of double-blind treatment, with good patient retention and acceptance of the treatment
MEDESIS PHARMA successfully completes Phase 2 clinical trial for Alzheimer's disease, announces Nanolithium scientific publication, participation in BIOMED Forum, and a new cash contribution

Medesis Pharma Phase 2 Clinical Trial Alzheimer's Disease Nanolithium BIOMED Forum
REGULATED PRESS RELEASE

published on 10/27/2023 at 18:00, 1 year ago

MEDESIS PHARMA: 2023 FIRST-HALF BUSINESS AND EARNINGS
REGULATED PRESS RELEASE

published on 10/23/2023 at 18:00, 1 year ago

MEDESIS PHARMA PARTICIPATES IN THE 16th INTERNATIONAL CONGRESS “CLINICAL TRIALS ON ALZHEIMER DISEASE” (CTAD) IN BOSTON FROM OCTOBER 24 TO 27, 2023 AND PRESENTS A POSTER ON ITS CURRENT RESEARCH
REGULATED PRESS RELEASE

published on 10/17/2023 at 08:00, 1 year 1 month ago

END OF ENROLLEMENT OF THE 68 PATIENTS IN MEDESIS PHARMA PHASE 2 CLINICAL STUDY OF NANOLITHIUM FOR THE TREATMENT OF ALZHEIMER’S DISEASE
REGULATED PRESS RELEASE

published on 10/11/2023 at 18:00, 1 year 1 month ago

MEDESIS PHARMA: PUBLICATION OF A SCIENTIFIC ARTICLE IN THE JOURNAL OF ALZHEIMER’S DISEASE ON THE USE OF LITHIUM FOR THE TREATMENT OF ALZHEIMER’S DISEASE

Accesswire

Published on 11/21/2024 at 10:03, 44 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 47 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 47 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 12 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 22 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:30, 17 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 42 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 45 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 47 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 47 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 49 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 27 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 17 hours 2 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 17 hours 2 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 3 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE